---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-001020"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2024-02-13T23:59:59+00:00"
generated_at: "2026-06-06T03:30:02.432469+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx receives $50M milestone from Janssen for bota-vec Phase 3 extension study

## Summary
- $50M milestone triggered by initiation of LUMEOS extension study for bota-vec (XLRP gene therapy).
- Additional $15M in near-term milestone payments expected later in 2024 from Janssen.
- Up to $285M further payments on first U.S./EU commercial sales and manufacturing tech transfer.
- Commercial supply agreement with J&J for bota-vec manufacturing expected to generate ongoing revenue.

## SEC filing metadata
- accession: 0001558370-24-001020
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2024-02-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837024001020/0001558370-24-001020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837024001020/mgtx-20240213x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-001020
- JSON: https://secwatch.observer/filing/0001558370-24-001020.json
- Plain text: https://secwatch.observer/filing/0001558370-24-001020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.